Protective Action of Liraglutide in Beta Cells Under Lipotoxic Stress Via PI3K/Akt/FoxO1 Pathway
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Liraglutide, a modified form of glucagon‐like peptide‐1 (GLP‐1), has been found to improve beta cell function in type 2 diabetes (T2DM). However, the effect of liraglutide on beta cell function under lipotoxic stress and the underlying molecular mechanisms remain unclear. In the present study, we investigated the role of PI3K/Akt/FoxO1 signaling in liraglutide‑involved beta cell protection in high free fatty acids (FFAs) condition. The apoptosis, proliferation, and insulin secretion capability of MIN6 cells and islets from C57BL/6J mice were evaluated when exposed to FFAs with/without liraglutide. The expression of effectors involved in PI3K/Akt/FoxO1signalling pathway was detected by real‐time PCR and western blotting in MIN6 cells and islets from C57BL/6J mice. Liraglutide substantially inhibited the lipoapoptosis and improved the proliferation and insulin secretion of beta cells in high FFAs condition. Western blot revealed that the phosphorylation of Akt and FoxO1 was markedly decreased under lipid stress but was elevated when treated with liraglutide. Moreover, FFAs could up‐regulate the expression levels of p27, Bax, Cidea but down‐regulate the expression levels of Pdx‐1, MafA, and NeuroD in beta cells, which was canceled by the addition of liraglutide. Moreover, LY294002, a PI3K inhibitor, could significantly abrogate all the protective actions of liraglutide against lipotoxicity. We concluded that liraglutide markedly improved beta cell function under lipid stress and that the protective action of liraglutide was mediated by activation of PI3K/Akt, which resulted in inactivation of FoxO1 along with the down‐regulation of p27, Bax, Cidea and up‐regulation of Pdx‐1, MafA, and NeuroD expressions. J. Cell. Biochem. 115: 1166–1175, 2014. © 2013 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Islet cell failure in type 2 diabetes
Prentki, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29103 · Cited by 1,690
(2004) · doi:10.1016/s0092-8674(04)00452-0 · Cited by 1,356
Thorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic β-cell mass
Buteau, J., Spatz, M. L., & Accili, D. (2006) · Diabetes · doi:10.2337/db05-0825 · Cited by 178
The emerging role of FOXO transcription factors in pancreatic β cells
Glauser, D. A., & Schlegel, W. (2007) · Journal of Endocrinology · doi:10.1677/joe-06-0191 · Cited by 153
Cited by
Recent Insights Into Mechanisms of β-Cell Lipo- and Glucolipotoxicity in Type 2 Diabetes
Lytrivi, M., Castell, A.-L., Poitout, V., & Cnop, M. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.09.016 · Cited by 408
GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
Ma, X., Liu, Z., Ilyas, I., Little, P. J., Kamato, D., Sahebka, A., Chen, Z., Luo, S., Zheng, X., Weng, J., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59965 · Cited by 299
The RISE Consortium, Ehrmann, D. A., Temple, K. A., Rue, A., Barengolts, E., Mokhlesi, B., Van Cauter, E., Sam, S., Miller, M. A., Kahn, S. E., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0556 · Cited by 73
Sun, Z., Li, P., Wang, X., Lai, S., Qiu, H., Chen, Z., Hu, S., Yao, J., & Shen, J. (2020) · International Journal of Endocrinology · doi:10.1155/2020/1484321 · Cited by 37
“Interaction between GLP-1 and FoxO1 has been reported in pancreatic B cells [19, 20].”
BackgroundZhang, W.-Q., Tian, Y., Chen, X.-M., Wang, L.-F., Chen, C.-C., & Qiu, C.-M. (2018) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-018-0392-8 · Cited by 27
Self-citation
Metadata
- Authors
- Shao, S., Nie, M., Chen, C., Chen, X., Zhang, M., Yuan, G., Yu, X., & Yang, Y.
- Venue
- Journal of Cellular Biochemistry
- Publisher
- Wiley
- Published
- 2014-04-15
- Volume
- 115
- Issue
- 6
- Pages
- 1166-1175
- ISSN
- 0730-2312 (ISSN-L)
- 1097-4644
- OpenAlex
- W1489126092
- Cited by
- 55
- References
- 5
- FWCI
- 4.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.